A registry study of elranatamab in Chinese patients with triple-class exposed relapsed/refractory multiple myeloma
Not Yet Recruiting NCT07320326
Study Description
ASPIRE Registry Study: Tracking the Real-World Effectiveness of Elranatamab Treatment in Chinese Multiple Myeloma Patients
Study Details
- Registry ID:
- NCT07320326
- Conditions:
- TCE-RRMM
- Phase:
- Target Enrollment:
- 159 participants
- Start Date:
- Age Range:
- 18–999 years
- Healthy Volunteers:
- No
Study Locations (1 site)
-
Peking University People's Hospital
Beijing, Beijing Municipality, China
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.